Literature DB >> 1526248

The dose-response relationship and therapeutic window for dizocilpine (MK-801) in a rat focal ischaemia model.

R H Hatfield1, R Gill, C Brazell.   

Abstract

The purpose of the present study was to examine the dose-response relationship and the maximum time for which effective therapy could be delayed for the N-methyl-D-aspartate antagonist dizocilpine (MK-801) as a neuroprotective agent in a permanent focal ischaemia model in the rat. The ED50 for dizocilpine in the amelioration of cortical damage in this model was found to be approximately 0.3 mg/kg (single i.p. dose, 30 min post onset of ischaemia) and significant protection was only obtained when therapy (3 mg/kg i.p.) was delayed for one hour or less after the onset of ischaemia. In a further experiment, dizocilpine 3 mg/kg i.p., produced a peak plasma level of 44 ng/ml and had a t1/2 elimination of 1.65 h.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1526248     DOI: 10.1016/0014-2999(92)90201-e

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects.

Authors:  Hongjie Yuan; Scott J Myers; Gordon Wells; Katherine L Nicholson; Sharon A Swanger; Polina Lyuboslavsky; Yesim A Tahirovic; David S Menaldino; Thota Ganesh; Lawrence J Wilson; Dennis C Liotta; James P Snyder; Stephen F Traynelis
Journal:  Neuron       Date:  2015-02-26       Impact factor: 17.173

Review 2.  Poly(ADP-ribose) polymerase: the nuclear target in signal transduction and its role in brain ischemia-reperfusion injury.

Authors:  Robert Piotr Strosznajder; Henryk Jesko; Agata Zambrzycka
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

3.  A3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats.

Authors:  In-Young Choi; Jae-Chul Lee; Chung Ju; Sunyoung Hwang; Geum-Sil Cho; Hyuk Woo Lee; Won Jun Choi; Lak Shin Jeong; Won-Ki Kim
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

4.  Production of leukotrienes in a model of focal cerebral ischaemia in the rat.

Authors:  P Ciceri; M Rabuffetti; A Monopoli; S Nicosia
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

5.  Poly(ADP-ribose) polymerase during reperfusion after transient forebrain ischemia: its role in brain edema and cell death.

Authors:  Robert P Strosznajder; Roman Gadamski; Grzegorz A Czapski; Henryk Jesko; Joanna B Strosznajder
Journal:  J Mol Neurosci       Date:  2003-02       Impact factor: 3.444

6.  Effects of riluzole on the evolution of focal cerebral ischemia: a magnetic resonance imaging study.

Authors:  I Mottet; R Demeure; J Rataud; M Lucas; F Wahl; V Warscotte; J P Thiran; J F Goudemant; B Maldague; J M Maloteaux; J M Stutzmann
Journal:  MAGMA       Date:  1997-09       Impact factor: 2.310

7.  Vicious cycle involving Na+ channels, glutamate release, and NMDA receptors mediates delayed neurodegeneration through nitric oxide formation.

Authors:  P J Strijbos; M J Leach; J Garthwaite
Journal:  J Neurosci       Date:  1996-08-15       Impact factor: 6.167

8.  Application of technetium-99m hexamethylpropylene amine oxime single-photon emission tomography to neurologic prognosis in patients undergoing urgent carotid surgery.

Authors:  I Y Shvera; A M Cherniavsky; W Y Ussov; M P Plotnikov; A A Sokolov; V M Shipulin; V I Chernov
Journal:  Eur J Nucl Med       Date:  1995-02

9.  Delayed treatment with carboxy-PTIO permits a 4-h therapeutic window of opportunity and prevents against ischemia-induced energy depletion following permanent focal cerebral ischemia in mice.

Authors:  E-Jian Lee; Yu-Chang Hung; Hung-Yi Chen; Tian-Shung Wu; Tsung-Ying Chen
Journal:  Neurochem Res       Date:  2008-12-14       Impact factor: 3.996

10.  Moderate hypoxia reduces pentylenetetrazol-induced seizures.

Authors:  C Rauca; H L Rüthrich
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.